Results 211 to 220 of about 16,333 (257)

Benefits of Direct-Acting Antivirals for Hepatitis C

Annals of Internal Medicine, 2017
Emerging data show that direct-acting antivirals (DAAs) improve clinical outcomes in hepatitis C virus (HCV).
Anna S, Lok, Raymond T, Chung, Hugo E, Vargas, Arthur Y, Kim, Susanna, Naggie, William G, Powderly   +5 more
openaire   +2 more sources

Management of direct-acting antiviral agent failures

Journal of Hepatology, 2015
Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance.
Maria, Buti, Mar, Riveiro-Barciela, Rafael, Esteban   +2 more
openaire   +2 more sources

Chronic Hepatitis C and Direct Acting Antivirals

Surgical Pathology Clinics, 2018
The hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is the most common cause of end-stage liver disease requiring liver transplant. Over the last 10 years, direct acting antiviral therapies have revolutionized HCV treatment, increasing the cure rates from less than 50% to more than 90% in those who reach access
Maria, Westerhoff, Joseph, Ahn
openaire   +2 more sources

Resistance to Direct-Acting Antivirals

Current Hepatitis Reports, 2012
Viral resistance corresponds to the selection, during treatment, of pre-existing viral variants less susceptible to the drug’s inhibitory activity because they bear amino acid substitutions altering the drug target. Hepatitis C virus (HCV) drugs in development can be split into two groups according to their barrier to resistance.
openaire   +1 more source

Resistance to direct-acting antiviral agents

Current Opinion in HIV and AIDS, 2015
This article examines the dynamics and factors underlying hepatitis C virus (HCV) resistance, along with their impact on daily clinical management of HCV-infected patients.Across available treatment-regimens, GT-3 is the most difficult-to-cure genotype, but also genotype-1a may show lower success-rates compared with genotype-1b.
Valeria, Cento, Stephane, Chevaliez, Carlo Federico, Perno   +2 more
openaire   +2 more sources

Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma

Surgical Oncology Clinics of North America
Therapy for chronic hepatitis C virus infection with direct-acting antiviral agents (DAAs) has been highly successful in achieving sustained virological response (SVR) with associated improvements in liver dysfunction, liver-related mortality, and transplant-free survival.
Ifrah, Fatima, Neehar D, Parikh, Alisa, Likhitsup   +2 more
openaire   +2 more sources

Direct acting antivirals failure: cause and retreatment options

Expert Review of Gastroenterology & Hepatology, 2018
Chronic hepatitis C (HCV) infection is a systemic life-threatening condition that can lead to hepatic and extra-hepatic complications. Sustained virological response (SVR) is associated with a regression of most liver and non-liver manifestations, which reduce mortality.
Lucia, Parlati, Stanislas, Pol
openaire   +2 more sources

Interferon free therapy with direct acting antivirals for HCV

Liver International, 2013
AbstractThe current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG‐IFN) plus ribavirin (RBV) regimen.
Tarik, Asselah, Patrick, Marcellin
openaire   +2 more sources

Direct-acting antiviral treatment for patients with hepatocellular carcinoma

Current Opinion in Gastroenterology, 2018
Hepatocellular carcinoma (HCC) affects a significant portion of patients with hepatitis C. The use of direct-acting antiviral (DAA) agents has transformed the disease outcomes in this patient group.Hepatitis C virus (HCV) response to DAAs can be affected by the presence of HCC, whereas DAA therapy may affect the risk of HCC recurrence in patients with ...
Tatyana, Kushner, Douglas, Dieterich, Behnam, Saberi   +2 more
openaire   +2 more sources

Extrahepatic manifestations of HCV: the role of direct acting antivirals

Expert Review of Anti-infective Therapy, 2017
Hepatitis C virus (HCV) represents a major health concern, as nearly 3 million people become newly infected by this pathogen annually. The majority of infected individuals fail to clear the virus, and chronicity is established. Chronic HCV patients are at high risk for liver disease, ranging from mild fibrosis to cirrhosis and severe hepatocellular ...
María Laura, Polo, Natalia, Laufer
openaire   +2 more sources